Month: April 2023

GÉNOMIQUE | THÉRAPIES CELLULAIRES & GÉNÉTIQUES | BIOPRODUCTION Genomic Vision rejoint France BioLead pour participer au développement et à l’innovation des produits biopharmaceutiques en France.L’intégration de Genomic Vision à France BioLead reflète la décision stratégique de la société de réorienter ses activités autour de l’innovation et l’accélération de la bioproduction. La technologie du peignage moléculaire est un outil unique et différenciateur pour la caractérisation de cellules transformées utilisé à des fins de bioproduction.Bagneux (France) – Genomic Vision (FR0011799907 – GV, la « Société »), société de biotechnologie cotée sur Euronext développant des produits et services dédiés à l’analyse et au contrôle des modifications du génome, a le plaisir d’annoncer son adhésion à France BioLead. L’Association France BioLead a...

  Drilling operations completed on first Hibiscus production well  BW Energy has completed the drilling and completion operations on DHIBM-3H, the first production well of the Hibiscus / Ruche Phase 1 development campaign in the Dussafu licence offshore Gabon. Responsibility for the DHIBM-3H well has been handed over to the production team which will finalise preparations for production start-up. First oil from the well is expected in early April. Commissioning and start-up of the new gas lift compressor will follow the first oil activities on the FPSO.  The DHIBM-3H well has been drilled from the BW MaBoMo production facility to a depth of 3,883 metres into Gamba sandstone reservoir in the Hibiscus field. Drilling operations began at the start of the year with batch setting of conductors and surface casing on three Hibiscus wells. In...

The Supervisory Board of AS Ekspress Grupp approved the group’s audited annual report 2022 and submits it to the General Meeting of Shareholders for approval. The financial results for 2022 remain unchanged compared to the preliminary disclosure on 15th February 2023. In 2022, the consolidated audited sales revenue of AS Ekspress Grupp totalled EUR 64.1 million which increased by 20% compared to 2021. Group’s consolidated audited net profit for 2022 totalled EUR 4.1 million. Digital revenues increased by 23% year-over-year and the share of digital revenues was 78% of the group’s total revenue. AS Ekspress Grupp audited annual report for 2022 is published in accordance with the European Single Electronic Format (ESEF) requirements as an XHTML file and as a PDF file. The Group’s primary statements and notes to statements are labelled...

      Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMDConversion of 160 ORNAN2022 by ESGO with intention to pursue controlled trading of shares Cost reduction measures implemented potentially extending the cash runway beyond the end of Q2 2023 Continuation of the fundraising process Breakthrough Device Designation status to streamline FDA regulatory review processParis, April 3, 2023 – 7:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, welcomes the interest of the market in the latest developments in its business following the announcement of the FDA Breakthrough Device Designation for the...

VEON Ltd. and VEON Holdings B.V. VEON obtains remaining licences required to amend its 2023 Notes and extend their maturities Amsterdam, Netherlands, 3 April 2023 07:00 CEST: VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, and its subsidiary, VEON Holdings B.V. (the “Company”), are pleased to announce that they have now received the remaining licences and regulatory confirmations required to implement the amendments to its 2023 Notes from UK, Dutch and Bermuda authorities. In addition to the OFAC Licence received on 23 December 2022, the OFSI Licence was received on 23 February 2023, a confirmation was received on 9 March 2023 from the Netherlands Ministry of Finance that a licence or authorisation is not required in connection with implementation of the...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor (the “Investor”) to sell 7,999,998 shares in the form of 1,333,333 American Depositary Shares (“ADSs”) at a gross purchase price of $0.95 per ADS. Each ADS represents six shares. Additionally, Addex has agreed to issue unregistered pre-funded warrants to purchase 3,929,825 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $0.94 with $0.01 payable on exercise as well as unregistered warrants to purchase up 5,263,158 ADSs (the “Unregistered Warrants” and together...

Lochem, 3 April 2023 ForFarmers announces changes in Executive BoardThe supervisory board of ForFarmers announces that Theo Spierings has to resign from his position as CEO due to health reasons and personal circumstances. Mr. Spierings has consequently decided to terminate his one-year contract prematurely. The supervisory board has appointed co-director Pieter Wolleswinkel as CEO of ForFarmers, effective from 3 April 2023. In addition, the supervisory board has decided to nominate Rob Kiers as member of the executive board, so that it will consist of three members again. An extraordinary general meeting of shareholders will be convened for this at short notice. Theo Spierings was appointed to member and CEO Of the executive board of ForFarmers on 17 January 2023 for the duration of one year. Jan van Nieuwenhuizen, chairman of the supervisory...

VEON Ltd. and VEON Holdings B.V. VEON confirms that Scheme Amendment Conditions have been satisfied Amsterdam, Netherlands, 3 April 2023 07:05 CEST: VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, and its subsidiary, VEON Holdings B.V. (the “Company”), are pleased to announce that, further to the announcement issued on 31 January 2023 regarding the Scheme becoming effective, each of the Amendment Conditions has been satisfied in accordance with the terms of the Scheme, including receipt by the Company of all authorisations and/or licences necessary to implement the amendments to the 2023 Notes (as set out in the Scheme). The Company is therefore proceeding with the steps required to implement the amendments to the 2023 Notes in accordance with the terms...

Notice is hereby given that the Management Board of AS Ekspress Grupp (registry code 10004677, official address Narva mnt 13, 10151 Tallinn) convenes the Annual General Meeting of Shareholders, which will be held on 4th of May, 2023 at 10:00 at the seat of AS Ekspress Grupp, in the city of Tallinn, Narva mnt 13, 4th floor. The registration of participants in the Meeting will commence at 9:30 at the location of the Meeting. The circle of shareholders entitled to attend the Annual General Meeting will be determined seven days prior to the General Meeting, i.e. on 27th April, 2023 at the end of the working day of the settlement system. The shareholders who do not participate in the meeting in person may vote electronically before the meeting. In order to vote using electronic means the shareholders are to fill in a voting ballot – the ballot...